Ciprofloxacin Intravenous Infusion B. P. 100ml

Name: Ciprofloxacin Intravenous Infusion B. P. 100ml
Brand: Shijiazhuang No. 4 Pharmaceutical Co., Ltd.
SKU: 2136915382

Hebei, ChinaShijiazhuang No. 4 Pharmaceutical Co., Ltd.

US$0.15

20,010 bottle

Sample price:US$0.15/bottle.Request sample

Product profile

Customization

Available

Application

Infusion

Usage Mode

Intravenous

Suitable for

Elderly, Children, Adult

State

Liquid

Shape

Bottle / Soft Bag / Bag

Type

Antibiotic Injection

Pharmaceutical Technology

Chemical Synthesis

Transport Package

Carton

Specification

100ml/bottle, 200mg Ciprofloxacin, B. P.

Origin

Hebei

Key features

1. B.P. Standard Compliance Manufactured in strict accordance with British Pharmacopoeia specifications, ensuring quality and acceptability in Commonwealth and B.P.-recognizing markets.

2. Broad-Spectrum Fluoroquinolone Activity Potent bactericidal action against Gram-negative and Gram-positive pathogens, including Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus.

3. Ready-to-Use IV Infusion Pre-mixed 200mg/100ml solution eliminates reconstitution errors, ideal for hospital wards, emergency departments, and intensive care units.

4. Multiple Clinical Indications Indicated for respiratory, urinary, gastrointestinal, skin, and bone infections, as well as septicemia and post-operative prophylaxis.

Company profile

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

Hebei, China

Business Type: Manufacturer/FactoryExport Year: 2002-01-01Nearest Port: Tianjin Xingang, Qingdao, ShanghaiAverage Response Time: ≤24hTerms of Payment: LC, T/TInternational Commercial Terms(Incoterms): FOB, CFR, CIF, CIP, EXW

AI-Powered supplier vetting

SummaryShijiazhuang No. 4 Pharmaceutical Co., Ltd. is identified as a Chinese public pharmaceutical manufacturer based in Hebei, with products spanning infusion solutions, injections, tablets, capsules, inhalation products, and other medical materials. The supplier reports ISO 9001, ISO 14001, and GMP certifications, more than ten production lines, automated and information-based production and logistics processes, and substantial stated output across several dosage forms. Its export activity began in 2002, although exports represent only 1%–10% of total sales. The company describes integrated R&D, manufacturing, and marketing capabilities, but the provided information does not establish specific after-sales programs, customization services, or named customer cases. Financial strength cannot be assessed because financial data is excluded.

Supplier typeThe supplier is explicitly classified as a Manufacturer/Factory and is described as an integrated pharmaceutical enterprise covering R&D, industrial production, and marketing. Its listed business covers health and medicine products, including injections, infusion solutions, tablets, capsules, and related dosage forms.

CertificationsThe supplier reports ISO 9001, ISO 14001, and GMP certifications. It also states that production is organized strictly according to GMP requirements, providing explicit evidence of formal quality, environmental, and pharmaceutical manufacturing systems.

R&D capabilityThe supplier describes an integrated R&D, production, and marketing model, reports 50 R&D engineers, and states that its production lines integrate leading equipment and technology at an international advanced level. This supports established technical and development capability, although no specific patents, new-product results, or R&D investment details are provided.

Production capacityProduction capability is strongly supported by more than ten production lines, automated and information-based production and logistics processes, and stated annual outputs of 1.5 billion large-volume injection units and 1 billion units each for tablets, capsules, and small-volume injections. The company also reports more than ten international advanced infusion-solution lines and exports through both agency and self-operated channels.

Product Q&A

Q:Who is your company?

We are Shijiazhuang No.4 Pharmaceutical Co., Ltd., established in 1948. We are a large-sized foreign-invested enterprise and comprehensive pharmaceutical manufacturer in China, with a registered capital of USD 58 million and over 3,000 employees.

Q:What is your main product range?

We manufacture 7 series of medicines covering more than 100 kinds and specifications, including large volume injections, capsules, granules, tablets, and oral liquids. Our key products include Dextrose 5% Injection, Dextrose 10% Injection, Dextrose 20% Injection, Ringer Lactate Injection, Metronidazole Injection, Sodium Chloride Injection, Glucose Saline Injection, Sterile Water for Injection, Compound Amino Acid Injection, Mannitol Injection, Sodium Bicarbonate Injection, Fluconazole Injection,

Q:What is your production capacity for large volume injections?

Our annual output for large volume I.V. solutions exceeds 1.2 billion bottles, including 40 million soft plastic bottles in dosages of 500ml, 250ml, and 100ml. Our quality, variety, and output are all in the leading position in China.